Researchers at the University of Haifa have synthesized recent advances in understanding Prader-Willi syndrome (PWS), highlighting its role as a crucial model for studying the genetic and neurobiological intersections between autism spectrum disorder (ASD) and psychotic spectrum disorders (PSD).
PWS affects males and females equally across ethnicities, with prevalence estimates ranging from about 1 in 16,000 to 1 in 76,000 births.
The syndrome arises from the lack of paternal gene expression in the chromosome 15q11-q13 region due to three genetic mechanisms: paternal deletions (65-75% of cases), maternal uniparental disomy (mUPD, 20-30%), and imprinting center defects (1-4%).
These genetic differences strongly influence psychiatric risk profiles. Individuals with deletions often exhibit autism-like traits, while those with mUPD show heightened vulnerability to psychosis, particularly in adolescence or adulthood.
Key genes within the PWS critical region contribute to brain development and psychiatric susceptibility. MAGEL2 impacts hypothalamic function and cognition, while NDN is essential for neuronal survival and breathing regulation.
CYFIP1, located in the 15q11.2 BP1-BP2 region, modulates the balance between neuronal excitation and inhibition and has been implicated in both ASD and schizophrenia. This suggests a possible common neurobiological pathway linking these disorders.
Neuroimaging studies reveal brain structural and functional differences in PWS patients that vary by genetic subtype. Those with deletions show gray matter reductions in areas like the orbitofrontal cortex and cerebellum, whereas mUPD cases exhibit disrupted connectivity in prefrontal-limbic circuits, resembling schizophrenia patterns.
These findings provide a biological basis for genotype-specific psychiatric risks and raise the possibility of early biomarkers for psychosis and autism susceptibility.
The review also highlights the promise of induced pluripotent stem cell (iPSC) models derived from PWS patients. These models allow real-time observation of how genetic variations affect neural development, revealing that autism and schizophrenia phenotypes diverge early but converge on synaptic deficits later.
This opens avenues for personalized medicine approaches, including testing targeted therapies based on genetic subtype.
Current PWS treatments focus on managing symptoms through hormone therapy, dietary control, and behavioral medications. However, emerging strategies such as gene editing, epigenetic modulation, and regenerative medicine aim to address underlying genetic causes.
Investigating therapies that restore neuronal excitation/inhibition balance could benefit both autism and psychosis symptoms. Artificial intelligence may also play a role in predicting individual treatment responses, advancing precision psychiatry.
Beyond PWS, these findings have broader implications for understanding neurodevelopmental and psychiatric disorders.
PWS serves as a controlled genetic model to dissect how specific gene variations shape brain development and psychiatric vulnerability, potentially informing diagnosis and treatment of more common conditions.
In summary, this expert review positions Prader-Willi syndrome as a vital model for exploring the genetic roots of autism and psychosis, advocating for integrated genetic, neuroimaging, and cellular research approaches to foster early detection and tailored interventions in psychiatric care.
Read More:
